Journal of the Formosan Medical Association
Volume 105, Issue 7 , Pages 588-593, 2006

Nonresponse to 18-month Lamivudine Monotherapy in Chronic Hepatitis B Patients with Dual Genotype B and C Infection and Acute Exacerbation

  • Jyh-Jou Chen

      Affiliations

    • Department of Internal Medicine, Chi Mei Hospital Liouying, Tainan, Taiwan
    • ,
  • Ling-Yu Tang

      Affiliations

    • Liver Research Unit, Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan
    • ,
  • Sun-Lung Tsai

      Affiliations

    • Liver Research Unit, Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Sun-Lung Tsai, Liver Research Unit, Department of Medical Research, Chi Mei Medical Center, 901, Chung Hwa Road, Yung Kang City, Tainan 710, Taiwan

Division of Hepatogastroenterology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan

Received 17 June 2005; received in revised form 28 July 2005; accepted 13 September 2005.

Molecular epidemiologic studies have indicated the possible existence of mixed infection of different hepatitis B virus (HBV) genotypes in chronic hepatitis B (CH-B) carriers, but the effect of dual HBV genotype B and C infection on the efficacy of lamivudine therapy remains unclear. We report four CH-B patients with dual HBV genotype B and C infection and acute exacerbation who received lamivudine monotherapy for about 18 months. None of them had achieved a sustained response at the end of the 18-month trial of treatment.

Key Words:  acute exacerbation , chronic hepatitis B , dual genotype infection , hepatitis B virus , lamivudine therapy , sustained response

No full text is available. To read the body of this article, please view the PDF online.

 

PII: S0929-6646(09)60155-8

doi:10.1016/S0929-6646(09)60155-8

Journal of the Formosan Medical Association
Volume 105, Issue 7 , Pages 588-593, 2006

Article Tools